Revolution Medicines (Revolution Medicines) FCF Margin % : -16,560.65% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Revolution Medicines FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Revolution Medicines's Free Cash Flow for the three months ended in Dec. 2023 was $-122.88 Mil. Revolution Medicines's Revenue for the three months ended in Dec. 2023 was $0.74 Mil. Therefore, Revolution Medicines's FCF Margin % for the quarter that ended in Dec. 2023 was -16,560.65%.

As of today, Revolution Medicines's current FCF Yield % is -5.49%.

The historical rank and industry rank for Revolution Medicines's FCF Margin % or its related term are showing as below:

RVMD' s FCF Margin % Range Over the Past 10 Years
Min: -3094.14 Med: -381.31 Max: -1.42
Current: -3094.14

During the past 7 years, the highest FCF Margin % of Revolution Medicines was -1.42%. The lowest was -3094.14%. And the median was -381.31%.

RVMD's FCF Margin % is ranked worse than
85.21% of 1041 companies
in the Biotechnology industry
Industry Median: -143.92 vs RVMD: -3094.14

Revolution Medicines FCF Margin % Historical Data

The historical data trend for Revolution Medicines's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revolution Medicines FCF Margin % Chart

Revolution Medicines Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-104.32

-239.62

-522.99

-664.83

-3,094.14

Revolution Medicines Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-421.81	-914.59	-1,784.52	-	-16,560.65

Competitive Comparison of Revolution Medicines's FCF Margin %

For the Biotechnology subindustry, Revolution Medicines's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revolution Medicines's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revolution Medicines's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Revolution Medicines's FCF Margin % falls into.

Revolution Medicines FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Revolution Medicines's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-358.301	/	11.58
	=	-3,094.14 %

Revolution Medicines's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-122.88	/	0.742
	=	-16,560.65 %

Revolution Medicines FCF Margin % Related Terms

Thank you for viewing the detailed overview of Revolution Medicines's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Revolution Medicines (Revolution Medicines) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revolution Medicines Inc (NAS:RVMD) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

42Z:Germany

Address

700 Saginaw Drive, Redwood City, CA, USA, 94063

Website

https://www.revmed.com

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Executives

Stephen Michael Kelsey	officer: See Remarks	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Jeff Cislini	officer: General Counsel	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mark A Goldsmith	director, officer: See Remarks	925 PAGE MILL ROAD, PALO ALTO CA 94304
Margaret A Horn	officer: See Remarks	925 PAGE MILL ROAD, PALO ALTO CA 94304
Jack Anders	officer: Chief Financial Officer	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Barbara Weber	director	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Xiaolin Wang	officer: See Remarks	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Thilo Schroeder	director	C/O NEXTECH INVEST LTD., BAHNHOFSTRASSE 18, ZURICH V8 8001
Lorence H. Kim	director	C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Sushil Patel	director	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK, THIRD FLOOR, WOBURN MA 01801
Third Rock Ventures Iii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Flavia Borellini	director	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Third Rock Ventures Ii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Peter Svennilson	director, 10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Vincent A. Miller	director	C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139